Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (6): 1243-1251.DOI: 10.19852/j.cnki.jtcm.20230904.004
• Research Articles • Previous Articles Next Articles
Mirror-like tongue is an important predictor of acute heart failure: a cohort study of acute heart failure in Chinese patients
CHEN Yunhu1, YIN Moqing1(
), FAN Lihua1(), JIANG Xuechun1, ZHANG Tao2, ZHU Xingyu3, XU Hongfeng1
- 1 Department of Cardiology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215400, China
2 Department of Cardiology, Changzhou Hospital affiliated with Nanjing University of Chinese Medicine, Changzhou 213003, China
3 Department of Clinical Pharmacy, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215400, China
-
Received:2022-08-11Accepted:2022-12-14Online:2023-10-25Published:2023-09-04 -
Contact:YIN Moqing, Department of Cardiology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215400, China. yinmoqing11@163.com; FAN Lihua, Department of Cardiology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215400, China. dellfanlihua@126.com. Telephone: +86-512-53728582 -
Supported by:2019 Suzhou Science and Technology Development Plan (the Fourth Batch of Basic Research on People's Livelihood, Science and Technology, and Medical and Health Applications): Applied Research on Diuretic Resistance of Zhuling Decoction(SYSD2019201)
Cite this article
CHEN Yunhu, YIN Moqing, FAN Lihua, JIANG Xuechun, ZHANG Tao, ZHU Xingyu, XU Hongfeng. Mirror-like tongue is an important predictor of acute heart failure: a cohort study of acute heart failure in Chinese patients[J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1243-1251.
share this article
Figure 1 Mirror-like tongue and normal tongue A: the typical mirror-like tongue in AHF patients, characterized by a complete lack of tongue fur and a glossy and clean surface with or without cracks; B: the tongue of another AHF patient, a lightred texture and thin white fur, is normal. AHF: acute heart failure.
Figure 1 Mirror-like tongue and normal tongue A: the typical mirror-like tongue in AHF patients, characterized by a complete lack of tongue fur and a glossy and clean surface with or without cracks; B: the tongue of another AHF patient, a lightred texture and thin white fur, is normal. AHF: acute heart failure.
Figure 2 Flow chart of the study MACE: major adverse cardiovascular event. Group A: mirror-like tongue group; Group B: non-mirror-like tongue group.
Figure 2 Flow chart of the study MACE: major adverse cardiovascular event. Group A: mirror-like tongue group; Group B: non-mirror-like tongue group.
Table 1 Baseline clinical features
| Clinical feature | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| Demographics | ||||
| Mean age (years, | 64±11 | 74±10 | 62±10 | <0.001 |
| Male [n (%)] | 200 (49.01) | 32 (49.23) | 168 (48.97) | 0.970 |
| Medical history [n (%)] | ||||
| Hypertension | 141 (34.56) | 23 (35.38) | 118 (34.40) | 0.879 |
| Diabetes mellitus | 102 (25.00) | 18 (27.69) | 84 (24.49) | 0.585 |
| Hyperlipemia | 209 (51.23) | 35 (53.85) | 174 (50.72) | 0.645 |
| Gout | 53 (12.99) | 8 (12.31) | 45 (13.12) | 0.858 |
| Stroke | 40 (9.80) | 7 (10.77) | 33 (9.62) | 0.775 |
| Atrial fibrillation, atrial flutter | 102 (25.00) | 17 (26.15) | 85 (24.78) | 0.844 |
| VT | 88 (21.56) | 13 (20.00) | 75 (21.86) | 0.737 |
| CHD | 92 (22.54) | 13 (20.00) | 79 (23.03) | 0.592 |
| Valvular heart disease | 176 (43.14) | 25 (38.46) | 151 (44.02) | 0.406 |
| Asthma | 46 (11.57) | 6 (9.23) | 40 (11.66) | 0.570 |
| COPD | 49 (12.01) | 8 (12.31) | 41 (11.95) | 0.936 |
| Kidney failure | 72 (17.64) | 11 (16.92) | 61 (17.78) | 0.867 |
| Anemia | 188 (46.07) | 27 (41.54) | 161 (46.94) | 0.423 |
| Infection | 67 (16.42) | 9 (13.85) | 58 (16.91) | 0.541 |
| Clinical signs | ||||
| SBP (mm Hg, | 130±26 | 125±25 | 131±27 | 0.071 |
| DBP (mm Hg, | 75±13 | 74±12 | 76±13 | 0.510 |
| HR (bpm, | 87±21 | 88±22 | 86±21 | 0.424 |
| RR (bpm, | 28±7 | 29±8 | 28±7 | 0.262 |
| NYHA [n (%)] | 0.909 | |||
| Ⅲ | 30 (7.35) | 5 (7.69) | 25 (7.29) | |
| Ⅳ | 378 (92.65) | 60 (92.31) | 318 (92.71) | |
| Ⅰ or Ⅱ | 0 (0.00) | 0 (0.00) | 0 (0.00) |
Table 1 Baseline clinical features
| Clinical feature | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| Demographics | ||||
| Mean age (years, | 64±11 | 74±10 | 62±10 | <0.001 |
| Male [n (%)] | 200 (49.01) | 32 (49.23) | 168 (48.97) | 0.970 |
| Medical history [n (%)] | ||||
| Hypertension | 141 (34.56) | 23 (35.38) | 118 (34.40) | 0.879 |
| Diabetes mellitus | 102 (25.00) | 18 (27.69) | 84 (24.49) | 0.585 |
| Hyperlipemia | 209 (51.23) | 35 (53.85) | 174 (50.72) | 0.645 |
| Gout | 53 (12.99) | 8 (12.31) | 45 (13.12) | 0.858 |
| Stroke | 40 (9.80) | 7 (10.77) | 33 (9.62) | 0.775 |
| Atrial fibrillation, atrial flutter | 102 (25.00) | 17 (26.15) | 85 (24.78) | 0.844 |
| VT | 88 (21.56) | 13 (20.00) | 75 (21.86) | 0.737 |
| CHD | 92 (22.54) | 13 (20.00) | 79 (23.03) | 0.592 |
| Valvular heart disease | 176 (43.14) | 25 (38.46) | 151 (44.02) | 0.406 |
| Asthma | 46 (11.57) | 6 (9.23) | 40 (11.66) | 0.570 |
| COPD | 49 (12.01) | 8 (12.31) | 41 (11.95) | 0.936 |
| Kidney failure | 72 (17.64) | 11 (16.92) | 61 (17.78) | 0.867 |
| Anemia | 188 (46.07) | 27 (41.54) | 161 (46.94) | 0.423 |
| Infection | 67 (16.42) | 9 (13.85) | 58 (16.91) | 0.541 |
| Clinical signs | ||||
| SBP (mm Hg, | 130±26 | 125±25 | 131±27 | 0.071 |
| DBP (mm Hg, | 75±13 | 74±12 | 76±13 | 0.510 |
| HR (bpm, | 87±21 | 88±22 | 86±21 | 0.424 |
| RR (bpm, | 28±7 | 29±8 | 28±7 | 0.262 |
| NYHA [n (%)] | 0.909 | |||
| Ⅲ | 30 (7.35) | 5 (7.69) | 25 (7.29) | |
| Ⅳ | 378 (92.65) | 60 (92.31) | 318 (92.71) | |
| Ⅰ or Ⅱ | 0 (0.00) | 0 (0.00) | 0 (0.00) |
Table 2 Auxiliary inspection parameters ($\bar{x}$ ± s)
| Parameter | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| LVEF (%) | 41.706±8.054 | 35.712±7.710 | 42.832±7.615 | <0.001 |
| Log NT-proBNP | 3.501±0.469 | 4.018±0.354 | 3.400±0.027 | <0.001 |
Table 2 Auxiliary inspection parameters ($\bar{x}$ ± s)
| Parameter | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| LVEF (%) | 41.706±8.054 | 35.712±7.710 | 42.832±7.615 | <0.001 |
| Log NT-proBNP | 3.501±0.469 | 4.018±0.354 | 3.400±0.027 | <0.001 |
Table 3 Hospitalization procedures
| Procedure | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| Combination of two or more vasoactive drugs [n (%)] | 173 (42.40) | 42 (64.62) | 131 (38.19) | <0.001 |
| Mechanical ventilation [n (%)] | 99 (24.26) | 22 (33.85) | 77 (22.45) | 0.049 |
| CAG [n (%)] | 112 (27.45) | 11 (16.92) | 101 (29.45) | 0.038 |
| Length of stay (days, | 8.5±3.6 | 13.1±3.6 | 7.6±2.9 | <0.001 |
Table 3 Hospitalization procedures
| Procedure | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| Combination of two or more vasoactive drugs [n (%)] | 173 (42.40) | 42 (64.62) | 131 (38.19) | <0.001 |
| Mechanical ventilation [n (%)] | 99 (24.26) | 22 (33.85) | 77 (22.45) | 0.049 |
| CAG [n (%)] | 112 (27.45) | 11 (16.92) | 101 (29.45) | 0.038 |
| Length of stay (days, | 8.5±3.6 | 13.1±3.6 | 7.6±2.9 | <0.001 |
Table 4 MACEs analysis [n (%)]
| MACEs | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| AHF recurred | 103 (25.25) | 25 (38.46) | 78 (22.74) | 0.007 |
| New nonfatal MI | 13 (3.19) | 6 (9.23) | 7 (2.04) | 0.009 |
| Stroke | 14 (3.43) | 8 (12.31) | 6 (1.75) | <0.001 |
| VT or VF | 12 (2.94) | 4 (6.15) | 8 (2.33) | 0.107 |
| All-cause death | 7 (1.72) | 2 (3.08) | 5 (1.46) | 0.309 |
Table 4 MACEs analysis [n (%)]
| MACEs | All (n = 408) | Group A (n = 65) | Group B (n = 343) | P value |
|---|---|---|---|---|
| AHF recurred | 103 (25.25) | 25 (38.46) | 78 (22.74) | 0.007 |
| New nonfatal MI | 13 (3.19) | 6 (9.23) | 7 (2.04) | 0.009 |
| Stroke | 14 (3.43) | 8 (12.31) | 6 (1.75) | <0.001 |
| VT or VF | 12 (2.94) | 4 (6.15) | 8 (2.33) | 0.107 |
| All-cause death | 7 (1.72) | 2 (3.08) | 5 (1.46) | 0.309 |
Table 5 Cox regression analysis
| Variable | Univariate Cox regression analysis HR (95% CI) | P value | Multivariate Cox regression analysis HR (95% CI) | P value |
|---|---|---|---|---|
| Mirror-like tongue | 2.452 (2.356, 2.553) | <0.001 | 2.341 (2.225, 2.462) | <0.001 |
| Length of hospital stay (for every 1 day increase) | 1.197 (1.193, 1.201) | <0.001 | 1.016 (1.010, 1.023) | <0.001 |
| Age (for every 1 year increase) | 1.124 (1.122, 1.126) | <0.001 | 1.028 (1.020, 1.036) | <0.001 |
| LVEF (for every 1% increase) | 0.830 (0.827, 0.832) | <0.001 | 0.929 (0.916, 0.942) | <0.001 |
| log NT-proBNP (for every 1 unit increase) | 16.454 (15.764, 17.175) | <0.001 | 4.279 (3.721, 4.922) | <0.001 |
Table 5 Cox regression analysis
| Variable | Univariate Cox regression analysis HR (95% CI) | P value | Multivariate Cox regression analysis HR (95% CI) | P value |
|---|---|---|---|---|
| Mirror-like tongue | 2.452 (2.356, 2.553) | <0.001 | 2.341 (2.225, 2.462) | <0.001 |
| Length of hospital stay (for every 1 day increase) | 1.197 (1.193, 1.201) | <0.001 | 1.016 (1.010, 1.023) | <0.001 |
| Age (for every 1 year increase) | 1.124 (1.122, 1.126) | <0.001 | 1.028 (1.020, 1.036) | <0.001 |
| LVEF (for every 1% increase) | 0.830 (0.827, 0.832) | <0.001 | 0.929 (0.916, 0.942) | <0.001 |
| log NT-proBNP (for every 1 unit increase) | 16.454 (15.764, 17.175) | <0.001 | 4.279 (3.721, 4.922) | <0.001 |
Figure 3 Cumulative hazard of MACEs The incidence of cumulative MACEs in group A was significantly higher than that in group B [HR = 2.76, 95% CI (1.73, 4.41), Log-rank test P < 0.001]. MACEs: major adverse cardiovascular events; HR: hazard ratio; CI: confidence interval.
Figure 3 Cumulative hazard of MACEs The incidence of cumulative MACEs in group A was significantly higher than that in group B [HR = 2.76, 95% CI (1.73, 4.41), Log-rank test P < 0.001]. MACEs: major adverse cardiovascular events; HR: hazard ratio; CI: confidence interval.
| 1. |
Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, Part 1: the epidemiology and risk factors. Circ Res 2017; 121: 677-94.
DOI PMID |
| 2. |
Leong DP, Joseph PG, McKee M, et al. Reducing the global burden of cardiovascular disease, Part 2: prevention and treatment of cardiovascular disease. Circ Res 2017; 121: 695-710.
DOI PMID |
| 3. |
Arrigo M, Jessup M, Mullens W, et al. Acute heart failure. Nat Rev Dis Primers 2020; 6: 16.
DOI PMID |
| 4. |
Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 2016; 13: 28-35.
DOI PMID |
| 5. |
Dharmarajan K, Hsieh AF, Kulkarni VT, et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ 2015; 350: h411.
DOI URL |
| 6. | Kitakata H, Kohno T, Kohsaka S, et al. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J Am Heart Assoc 2020; 9: e014949. |
| 7. |
Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res 2021; 128: 1468-86.
DOI PMID |
| 8. |
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021; 128: 1421-34.
DOI PMID |
| 9. | Parenica J, Spinar J, Vitovec J, et al. Long-term survival following acute heart failure: the acute heart failure database main registry (AHEAD Main). Eur J Intern Med 2013; 24: 151-60. |
| 10. |
Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail 2021; 14: e008406.
DOI URL |
| 11. |
Liang X, Wang Q, Jiang Z, et al. Clinical research linking Traditional Chinese Medicine constitution types with diseases: a literature review of 1639 observational studies. J Tradit Chin Med 2020; 40: 690-702.
DOI PMID |
| 12. | Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975. |
| 13. |
Li ZG. Comparative study on WHO western pacific region and world federation of Chinese medicine societies international standard terminologies on traditional medicine: diseases in internal medicine (part 1). Zhong Xi Yi Jie He Xue Bao 2012; 10: 471-6.
DOI URL |
| 14. | Bing Z, Hongcai W. Diagnostics of Traditional Chinese Medicine. Beijing: People's Military Medical Press, 2010: 47. |
| 15. | Ojo A, Tariq S, Harikrishnan P, Iwai S, Jacobson JT. Cardiac resynchronization therapy for heart failure. Interv Cardiol Clin 2017; 6: 417-26. |
| 16. |
Chatterjee NA, Poole JE. Cardiac resynchronization therapy in nonischemic cardiomyopathy: To D or P? JACC Heart Fail 2021; 9: 450-2.
DOI URL |
| 17. |
Cai J, Zeng DJB. Sample size/power calculation for case-cohort studies. Biometrics 2004; 60: 1015-24.
PMID |
| 18. |
Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail 2020; 8: 523-36.
DOI URL |
| 19. |
Baman JR, Ahmad FS. Heart failure. JAMA 2020; 324: 1015.
DOI URL |
| 20. |
Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020; 17: 269-85.
DOI PMID |
| 21. |
Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 2020; 17: 641-55.
DOI PMID |
| 22. |
Chen YH, Fan LH, Zhang T, Liu XQ. Effectiveness of Zhuling decoction on diuretic resistance in patients with heart failure: a randomized, controlled trial. J Tradit Chin Med 2022; 42: 439-45.
DOI PMID |
| 23. |
Lo LC, Cheng TL, Chen YJ, Natsagdorj S, Chiang JY. TCM tongue diagnosis index of early-stage breast cancer. Complement Ther Med 2015; 23: 705-13.
DOI URL |
| 24. |
Song AY, Lou YN, Yang QX, et al. Diagnosis of early esophageal cancer based on TCM tongue inspection. Biomed Environ Sci 2020; 33: 718-22.
DOI PMID |
| 25. |
Hsu PC, Wu HK, Huang YC, et al. The tongue features associated with type 2 diabetes mellitus. Medicine (Baltimore) 2019; 98: e15567.
DOI URL |
| 26. | Yin HH. Basic theories of Chinese medicine. Shanghai: Shanghai science and technology press, 1984: 44-5. |
| 27. | Shang B, Zhang H, Lu Y, et al. Insights from the perspective of Traditional Chinese Medicine to elucidate association of lily disease and Yin deficiency and internal heat of depression. Evid Based Complement Alternat Med 2020; 2020: 8899079. |
| 28. |
Park YJ, Cho SW, Lee BH, Park YB. Development and validation of the Yin deficiency scale. J Altern Complement Med 2013; 19: 50-6.
DOI URL |
| 29. |
Li H, Sun J, Wang X, Shi J. Oral microbial diversity analysis among atrophic glossitis patients and healthy individuals. J Oral Microbiol 2021; 13: 1984063.
DOI URL |
| 30. |
Chiang CP, Chang JY, Wang YP, Wu YH, Wu YC, Sun A. Atrophic glossitis: etiology, serum autoantibodies, anemia, hematinic deficiencies, hyperhomocysteinemia, and management. J Formos Med Assoc 2020; 119: 774-80.
DOI URL |
| 31. |
Hsu MF, Tang PL, Pan TC, Hsueh KC. Different traditional Chinese medicine constitution is associated with dietary and lifestyle behaviors among adults in Taiwan. Medicine (Baltimore) 2022; 101: e30692.
DOI URL |
| 32. |
Liu J, Xu F, Mohammadtursun N, Lü Y, Tang Z, Dong J. The analysis of constitutions of Traditional Chinese Medicine in relation to cerebral infarction in a Chinese sample. J Altern Complement Med 2018; 24: 458-62.
DOI URL |
| 33. | Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. J Altern Complement Med Lancet 2020; 395: 709-33. |
| 34. |
Ponikowski P, Jankowska EA. Targeting iron deficiency in heart failure: existing evidence and future expectations. Circ Heart Fail 2021; 14: e008299.
DOI URL |
| 35. | Parahiba SM, Spillere SR, Zuchinali P, et al. Handgrip strength in patients with acute decompensated heart failure: accuracy as a predictor of malnutrition and prognostic value. Nutrition 2021; 91-92: 111352. |
| 36. |
Jeejeebhoy KN. Malnutrition in patients with heart failure. Am J Clin Nutr 2021; 113: 501-2.
DOI PMID |
| 37. | Arnold SV, Khunti K, Bonnet F, et al. Type2 diabetes and heart failure: insights from the global DISCOVER study. ESC Heart Fail 2021; 8: 1711-16. |
| 38. |
Merino-Merino A, Gonzalez-Bernal J, Fernandez-Zoppino D, Saez-Maleta R, Perez-Rivera JA. The role of galectin-3 and ST2 in cardiology: a short review. Biomolecules 2021; 11: 1167.
DOI URL |
| [1] | TIAN Xinrong, HOU Runsu, LIU Xinguang, ZHAO Peng, TIAN Yange, LI Jiansheng. Yangqing Chenfei formula (养清尘肺方) alleviates crystalline silica induced pulmonary inflammation and fibrosis by suppressing macrophage polarization [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1126-1139. |
| [2] | HE Yun, HE Jing, XU Xiangru, LI Haixiao, SHI Rongwei, LIANG Junya, ZHOU Ying, ZHU Yao, CHEN Xiaohu, TANG Shuhua, XIAO Min, ZHAN Libin, PEI Yinghao, JIANG Weiming. Consensus on diagnostic criteria for Yin deficiency syndrome in hypertension: a modified Delphi study [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 181-187. |
| [3] | ZHU Lingyan, WEI Yihong, WANG Youhua, YANG Jianmei, LI Jiawei, CAO Min, ZHOU Duan. Protective efficacy of Shenge San (参蛤散) on mitochondria in H9c2 cardiomyocytes [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 892-899. |
| [4] | ZHANG Jiaying, WEI Xiangxiang, LI Xuefeng, YUAN Yang, DOU Yinghuan, SHI Yanbin, XIE Ping, ZHOU Mengru, ZHAO Junnan, LI Miao, ZHANG Shuwen, ZHU Rui, TIAN Ying, TAN Hao, TIAN Feifei. Shunxin decoction (顺心组方) improves diastolic function in rats with heart failure with preserved ejection fraction induced by abdominal aorta constriction through cyclic guanosine monophosphate-dependent protein kinase Signaling Pathway [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 764-772. |
| [5] | CHEN Yunhu, FAN Lihua, ZHANG Tao, LIU Xueqian. Effectiveness of Zhuling decoction (猪苓汤) on diuretic resistance in patients with heart failure: a randomized, controlled trial [J]. Journal of Traditional Chinese Medicine, 2022, 42(3): 439-445. |
| [6] | WANG Wei, LI Qingling, MA Qiang, XIA Ran, GAO Bing, WANG Yi, WANG Jing. Effects of moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) combined with benazepril on myocardial cells apoptosis index and apoptosis-related proteins cytochrome c and apoptosis-inducing factor in rats with chronic heart failure [J]. Journal of Traditional Chinese Medicine, 2022, 42(2): 227-233. |
| [7] | Fu Mingming, Wang Zhiqian, Liu Yan. Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures [J]. Journal of Traditional Chinese Medicine, 2020, 40(5): 870-874. |
| [8] | Li Xiaoqian, Huang Pinxian, Wang Shijun, Cao Xuebin, He Jiancheng. Transforming growth factor β1 is a differentially expressed candidate protein of congestive heart failure with Qi-deficiency-blood-stasis syndrome [J]. Journal of Traditional Chinese Medicine, 2020, 40(2): 311-316. |
| [9] | Yu Mei, Guo Hangyuan, Ye Lingling, Bian Jiaping, Ma Lijuan, Zheng Chunli. Effect of Jiawei Shenfu decoction on tumor necrosis factor-alpha and nuclear factor-kappa B in patients who have chronic heart failure with syndromes of deficiency of heart Yang [J]. Journal of Traditional Chinese Medicine, 2019, 39(03): 418-424. |
| [10] | Gao Ling, Yang Ting, Zhu Jiaqi, Xu Lei, Su Li, Wang Di. Effect of Qiangxin Huoli decoction on rats with adriamycin-induced chronic heart failure [J]. Journal of Traditional Chinese Medicine, 2019, 39(01): 81-88. |
| [11] | Liu Yaru, Zhao Jianxin, Tian Yuanxiang. Efficacy and safety of electroacupuncture in treatment of lumbar disc herniation: a protocol for a cohort study [J]. Journal of Traditional Chinese Medicine, 2019, 39(01): 127-132. |
| [12] | Gao Wulin, Dai Guohua, Zhang Tong, Bi Dongxue, Liu Chunhua, Shi Xiaojing, Zhao Fang, Zhao Chen. Tonifying Qi and activating blood circulation in terms of Traditional Chinese Medicine: their effects in patients with myocardial infarction [J]. Journal of Traditional Chinese Medicine, 2018, 38(05): 726-732. |
| [13] | Guo Yuhong, Di Tingting, Zhao Jingxia, Xu Xiaolong, Li Ping, Huang Lijuan, Liu Qingquan. Fuxin decoction attenuates doxorubicin-induced heart failure in rats via oxidizing suppression and regulating immune responses [J]. Journal of Traditional Chinese Medicine, 2018, 38(04): 579-584. |
| [14] | Dai Guohua, Gao Wulin, Bi Dongxue, Liu Chunhua, Liu Yuhan, Wang Ning, Zhao Chen. Efficacy of Traditional Chinese Medicine in patients with acute myocardial infarction suffering from diabetes mellitus [J]. Journal of Traditional Chinese Medicine, 2018, 38(03): 412-418. |
| [15] | Wang Xianliang, Hou Yazhu, Mao Jingyuan, Zhao Yingqiang, Niu Tianfu, Yuan Ruyu, Wang Yonggang, Cui Jinrong, Shi Le, Jia Xiuli, Fan Ruihong, Lin Qian, Zhang Yan, Li Zhijun, Shang Hongcai, Wang Baohe, Wang Hongwu, Wang Henghe, Cui Xiaolei, Soh Shanbin, Ruan Jishou, Zhang Boli. Western medication plus Traditional Chinese Medicine preparations in patients with chronic heart failure: a prospective, single-blind,randomized, controlled, and multicenter clinical trial [J]. Journal of Traditional Chinese Medicine, 2017, 37(06): 756-766. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
